Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 177

The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.

Factors affecting Aβ plasma levels and their utility as biomarkers in ADNI

Open access
Toledo, Jon B., Vanderstichele, Hugo, Figurski, Michal, Aisen, Paul S., Petersen, Ronald C., Weiner, Michael W., Jack, Clifford R., Jagust, William, Decarli, Charles, Toga, Arthur W., Toledo, Estefanía, Xie, Sharon X., Lee, Virginia M.-Y., Trojanowski, John Q., Shaw, Leslie M.·2011·Acta Neuropathologica
DOI 10.1007/s00401-011-0861-8
Open this paper in CoChat — free account

Abstract

Previous studies of Aβ plasma as a biomarker for Alzheimer’s disease (AD) obtained conflicting results. We here included 715 subjects with baseline Aβ1-40 and Aβ1-42 plasma measurement (50% with 4 serial annual measurements): 205 cognitively normal controls (CN), 348 patients mild cognitive impairment (MCI) and 162 with AD. We assessed the factors that modified their concentrations and correlated these values with PIB PET, MRI and tau and Aβ1-42 measures in cerebrospinal fluid (CSF). Association between Aβ and diagnosis (baseline and prospective) was assessed. A number of health conditions were associated with altered concentrations of plasma Aβ. The effect of age differed according to AD stage. Plasma Aβ1-42 showed mild correlation with other biomarkers of Aβ pathology and were associated with infarctions in MRI. Longitudinal measurements of Aβ1-40 and Aβ1-42 plasma levels showed modest value as a prognostic factor for clinical progression. Our longitudinal study of complementary measures of Aβ pathology (PIB, CSF and plasma Aβ) and other biomarkers in a cohort with an extensive neuropsychological battery is significant because it shows that plasma Aβ measurements have limited value for disease classification and modest value as prognostic factors over the 3-year follow-up. However, with longer follow-up, within subject plasma Aβ measurements could be used as a simple and minimally invasive screen to identify those at increased risk for AD. Our study emphasizes the need for a better understanding of the biology and dynamics of plasma Aβ as well as the need for longer term studies to determine the clinical utility of measuring plasma Aβ.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s00401-011-0861-8

Cites

10 of 10 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 10 references

Research works printed but not linked: 45

  1. (1998) Consensus report of the Working Group on: “Molecular and Biochemical Markers of Alzheimer’s Disease”. The Ronald and Nancy Reagan Research Institute of the Alzheimer’s Association and the National Institute on Aging Working Group. Neurobiology of aging 19(2): 109–116 · DOI · Paper page
  2. Arvanitakis Z, Lucas JA, Younkin LH, Younkin SG, Graff-Radford NR (2002) Serum creatinine levels correlate with plasma amyloid [beta] protein. Alzheimer Dis Assoc Disord 16(3):187–190 · DOI
  3. Blasko I, Kemmler G, Krampla W et al (2005) Plasma amyloid [beta] protein 42 in non-demented persons aged 75 years: effects of concomitant medication and medial temporal lobe atrophy. Neurobiol Aging 26(8):1135–1143 · DOI
  4. Blennow K, De Meyer G, Hansson O et al (2009) Evolution of Abeta42 and Abeta40 levels and Abeta42/Abeta40 ratio in plasma during progression of Alzheimer’s disease: a multicenter assessment. J Nutr Health Aging 13(3):205–208 · DOI
  5. Butters N, Granholm E, Salmon D, Grant I, Wolfe J (1987) Episodic and semantic memory: a comparison of amnesic and demented patients. J Clin Exp Neuropsychol 9(5):479–497 · DOI · Paper page
  6. Cosentino SA, Stern Y, Sokolov E et al (2010) Plasma {beta}-amyloid and cognitive decline. Arch Neurol 67(12):1485–1490 · DOI
  7. Chen M, Inestrosa NC, Ross GS, Fernandez HL (1995) Platelets are the primary source of amyloid [beta]-peptide in human blood. Biochem Biophys Res Commun 213(1):96–103 · DOI · Paper page
  8. de Souza LC, Lamari F, Belliard S et al (2011) Cerebrospinal fluid biomarkers in the differential diagnosis of Alzheimer’s disease from other cortical dementias. J Neurol Neurosurg Psychiatry 82(3):240–246 · DOI · Paper page
  9. Devanand DP, Schupf N, Stern Y et al (2011) Plasma Aβ and PET PiB binding are inversely related in mild cognitive impairment. Neurology · DOI
  10. Fagan AM, Mintun MA, Shah AR et al (2009) Cerebrospinal fluid tau and ptau(181) increase with cortical amyloid deposition in cognitively normal individuals: implications for future clinical trials of Alzheimer’s disease. EMBO Mol Med 1(8–9):371–380 · DOI · Paper page
  11. Fagan AM, Shaw LM, Xiong C et al (2011) Comparison of Analytical Platforms for Cerebrospinal Fluid Measures of {beta}-Amyloid 1-42, Total tau, and P-tau181 for Identifying Alzheimer Disease Amyloid Plaque Pathology. Arch Neurol · DOI · Paper page
  12. Fei M, Jianghua W, Rujuan M, Wei Z, Qian W (2011) The relationship of plasma A[beta] levels to dementia in aging individuals with mild cognitive impairment. J Neurol Sci 305(1–2):92–96 · DOI
  13. Folstein MF, Folstein SE, McHugh PR (1975) Mini-mental state. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12(3):189–198 · DOI · Paper page
  14. Fukumoto H, Tennis M, Locascio JJ et al (2003) Age but not diagnosis is the main predictor of plasma amyloid {beta}-protein levels. Arch Neurol 60(7):958–964 · DOI · Paper page
  15. Goldberg KM, Iglewicz B (1992) Bivariate extensions of the boxplot. Technometrics 34:307–320 · doi:10.2307/1270037
  16. Goodglass H, Kaplan E (1983) The assessment of aphasia and related disorders. Lea & Febiger, Philadelphia
  17. Graff-Radford NR, Crook JE, Lucas J et al (2007) Association of low plasma Abeta42/Abeta40 Ratios with increased imminent risk for mild cognitive impairment and alzheimer disease. Arch Neurol 64(3):354–362 · DOI · Paper page
  18. Jagust WJ, Bandy D, Chen K et al (2010) The Alzheimer’s disease neuroimaging Initiative positron emission tomography core. Alzheimers Dement 6(3):221–229 · DOI · Paper page
  19. Kaplan E, Goodglass H, Weintraub S (1983) Boston naming test. Lea & Febiger, Philadelphia
  20. Lachno DR, Vanderstichele H, De Groote G et al (2009) The influence of matrix type, diurnal rhythm and sample collection and processing on the measurement of plasma beta-amyloid isoforms using the INNO-BIA plasma Abeta forms multiplex assay. J Nutr Health Aging 13(3):220–225 · DOI
  21. Lambert J-C, Schraen-Maschke S, Richard F et al (2009) Association of plasma amyloid β with risk of dementia. Neurology 73(11):847–853 · DOI
  22. Lambert JC, Dallongeville J, Ellis KA et al (2011) Association of plasma aβ peptides with blood pressure in the elderly. PLoS ONE 6(4):e18536 · DOI
  23. Laske C, Sopova K, Gkotsis C et al (2010) Amyloid-β peptides in plasma and cognitive decline after 1 year follow-up in alzheimer’s disease patients. J Alzheimers Dis 21(4):1263–1269 · DOI
  24. Lewczuk P, Kornhuber J, Vanmechelen E et al (2010) Amyloid beta peptides in plasma in early diagnosis of Alzheimer’s disease: a multicenter study with multiplexing. Exp Neurol 223(2):366–370 · DOI
  25. Locascio JJ, Fukumoto H, Yap L et al (2008) Plasma amyloid {beta}-protein and c-reactive protein in relation to the rate of progression of Alzheimer disease. Arch Neurol 65(6):776–785 · DOI
  26. Lopez OL, Kuller LH, Mehta PD et al (2008) Plasma amyloid levels and the risk of AD in normal subjects in the Cardiovascular Health Study. Neurology 70(19):1664–1671 · DOI · Paper page
  27. Lui JK, Laws SM, Li Q-X et al (2010) Plasma amyloid-β as a biomarker in Alzheimer’s disease: the AIBL study of aging. J Alzheimers Dis 20(4):1233–1242 · DOI
  28. Mathis CA, Wang Y, Holt DP et al (2003) Synthesis and Evaluation of 11C-Labeled 6-Substituted 2-Arylbenzothiazoles as Amyloid Imaging Agents. J Med Chem 46(13):2740–2754 · DOI · Paper page
  29. Mayeux R, Tang M-X, Jacobs DM et al (1999) Plasma amyloid β-peptide 1-42 and incipient Alzheimer’s disease. Ann Neurol 46(3):412–416 · doi:10.1002/1531-8249(199909)46:3<412::aid-ana19>3.0.co;2-a
  30. Mehta PD, Pirttila T, Patrick BA, Barshatzky M, Mehta SP (2001) Amyloid [beta] protein 1-40 and 1-42 levels in matched cerebrospinal fluid and plasma from patients with Alzheimer disease. Neurosci Lett 304(1–2):102–106 · DOI · Paper page
  31. Reitan R (1958) Validity of the trail making test as an indicator of organic brain damage. Percept Mot Skills 8:271–276 · DOI · Paper page
  32. Rentz DM, Locascio JJ, Becker JA et al (2010) Cognition, reserve, and amyloid deposition in normal aging. Ann Neurol 67(3):353–364 · DOI
  33. Rey A (1964) L’examen clinique en psychologie. Presses Universitaires de France, Paris
  34. Rosen W, Mohs R, Davis K (1984) A new rating scale for Alzheimer’s disease. Am J Psychiatry 141(11):1356–1364 · DOI · Paper page
  35. Ryan JR, Paolo AM (1992) A screening procedure for estimating premorbid intelligence in the elderly. Clin Neuropsychol 6(1):53–62 · DOI
  36. Schupf N, Tang MX, Fukuyama H et al (2008) Peripheral Aβ subspecies as risk biomarkers of Alzheimer’s disease. Proc Nat Acad Sci 105(37):14052–14057 · DOI · Paper page
  37. Schupf N, Zigman WB, Tang M-X et al (2010) Change in plasma Aβ peptides and onset of dementia in adults with Down syndrome. Neurology 75(18):1639–1644 · DOI
  38. Seppälä TT, Herukka S-K, Hänninen T et al (2010) Plasma Aβ42 and Aβ40 as markers of cognitive change in follow-up: a prospective, longitudinal, population-based cohort study. J Neurol Neurosurg Psychiatry 81(10):1123–1127 · DOI
  39. Shaw LM, Vanderstichele H, Knapik-Czajka M et al (2011) Qualification of the analytical and clinical performance of CSF biomarker analyses in ADNI. Acta Neuropathol 121(5):597–609 · DOI · Paper page
  40. Sundelof J, Giedraitis V, Irizarry MC et al (2008) Plasma beta amyloid and the risk of alzheimer disease and dementia in elderly men: a prospective, population-based cohort study. Arch Neurol 65(2):256–263 · DOI
  41. Taylor K, Salmon D, Rice V et al (1996) Longitudinal examination of american national adult reading test (AMNART) performance in dementia of the Alzheimer type (DAT): validation and correction based on degree of cognitive decline. J Clin Exp Neuropsychol 18(6):883–891 · DOI
  42. Van Dijk EJ, Prins ND, Vermeer SE et al (2004) Plasma amyloid β, apolipoprotein E, lacunar infarcts, and white matter lesions. Ann Neurol 55(4):570–575 · DOI
  43. van Oijen M, Hofman A, Soares HD, Koudstaal PJ, Breteler MM (2006) Plasma Abeta(1-40) and Abeta(1-42) and the risk of dementia: a prospective case-cohort study. Lancet Neurol 5(8):655–660 · DOI · Paper page
  44. Weigand SD, Vemuri P, Wiste HJ et al (2011) Transforming cerebrospinal fluid Abeta42 measures into calculated Pittsburgh compound B units of brain Abeta amyloid. Alzheimers Dement 7(2):133–141 · DOI · Paper page
  45. Yaffe K, Weston A, Graff-Radford NR et al (2011) Association of plasma β-amyloid level and cognitive reserve with subsequent cognitive decline. JAMA 305(3):261–266 · DOI · Paper page

Cited by

See all 177

Metadata

Authors
Toledo, J. B., Vanderstichele, H., Figurski, M., Aisen, P. S., Petersen, R. C., Weiner, M. W., Jack, C. R., Jagust, W., Decarli, C., Toga, A. W., Toledo, E., Xie, S. X., Lee, V. M.-Y., Trojanowski, J. Q., & Shaw, L. M.
Venue
Acta Neuropathologica
Publisher
Springer Science and Business Media LLC
Published
2011-07-30
Volume
122
Issue
4
Pages
401-13
ISSN
  • 0001-6322 (ISSN-L)
  • 1432-0533
DOI
10.1007/s00401-011-0861-8
OpenAlex
W1985879372
Cited by
177
References
10
FWCI
8.08
Type
journal article
Language
en
Open access
green
Licence
www.springer.com/tdm (tdm)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Factors affecting Aβ plasma levels and their utility as biomarkers in ADNI. https://app.cochat.ai/papers/10.1007/s00401-011-0861-8
The paper
Toledo, J. B., Vanderstichele, H., Figurski, M., Aisen, P. S., Petersen, R. C., Weiner, M. W., Jack, C. R., Jagust, W., Decarli, C., Toga, A. W., Toledo, E., Xie, S. X., Lee, V. M.-Y., Trojanowski, J. Q., & Shaw, L. M. (2011). Factors affecting Aβ plasma levels and their utility as biomarkers in ADNI. Acta Neuropathologica. https://doi.org/10.1007/s00401-011-0861-8

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.